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Abstract
Background: Domestic Violence and Abuse (DVA) is associated with a range of psychosocial and mental health
problems. Having a psychiatric illness increases likelihood of being a victim of DVA. Despite the evidence of a high
risk for DVA and the serious effects of violent victimization in psychiatric patients, detection rates are low and
responses are inadequate. The aim of the BRAVE (Better Reduction trough Assessment of Violence and Evaluation)
study is to improve detection of and response to DVA in psychiatric patients. In this article, we present the protocol
of the BRAVE study which follows the SPIRIT guidelines.
Methods: The BRAVE study is a cluster randomized controlled trial. We will include 24 community mental health
teams from Rotterdam and The Hague. Twelve teams will provide care as usual and 12 teams will receive the
intervention. The intervention consists of 1) a knowledge and skills training for mental health professionals about
DVA, 2) a knowledge and skills training of DVA professionals about mental illness, 3) provision and implementation
of a referral pathway between community mental health and DVA services. The follow up period is 12 months. Our
primary outcome is the rate of detected cases of recent or any history of DVA in patients per team in 12 months.
Detection rates are obtained through a systematic search in electronic patient files. Our secondary aims are to
obtain information about the gain and sustainability of knowledge on DVA in mental health professionals, and to
obtain insight into the feasibility, sustainability and acceptability of the intervention. Data on our secondary aims
will be obtained through structured in depth interviews and a questionnaire on knowledge and attitudes on DVA.
Discussion: This study is the first cluster randomized controlled trial to target both male and female psychiatric
patients that experience DVA, using an intervention that involves training of professionals. We expect the rate of
detected cases of DVA to increase in the intervention teams. With early detection of victimization of DVA in
psychiatric patients we hope to improve the mental health of psychiatric patients in the short and long term.
Trial registration: ISRCTN:14115257. Date of registration: 15th January 2015.
Keywords: Psychiatry, Domestic violence, Intervention, Victimization, Detection, Patients, Outpatient, Community
mental health teams, Randomized clinical trial
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Background
Domestic Violence and Abuse (DVA) is a major public
health concern which affects the lives of people across
the globe [1]. In the Netherlands approximately 45% of
all persons experience at least one form of DVA during
their life time and estimates suggest that approximately
200.000 Dutch persons per year are victimized by an in-
timate partner or family member [2]. DVA is the most
prevalent form of violence and affects men, women and
children in all segments of society.
The definition of DVA can vary. DVA can be defined
as ‘any incident of threatening behaviour, violence or
abuse (psychological, physical, sexual, financial or emo-
tional) between adults who are or have been an intimate
partner, family member, friend or otherwise closely
related (i.e. a care taker or roommate) [3].
In addition to immediate physical injuries and long
term conditions such as chronic pain (e.g. back or neck),
gynaecologic problems such as chronic pelvic pain or
sexually-transmitted diseases and hypertension [4–11],
DVA is associated with a range of psychosocial and
mental health problems, including loneliness, anxiety,
depression, post-traumatic stress disorders, substance
abuse and psychosis which can be transient as well as
chronic [4, 12–15] [16–18].
Research has found a high prevalence of DVA among
psychiatric patients [19] and, across all diagnostic
categories, an increased likelihood of being a victim of
DVA among women and men with psychiatric disorders
[13, 20]. Results from the Dutch nationwide study on
victimization in psychiatric patients supports the results
and mentioned reports a 6-fold increase of DVA in
severely mentally ill (SMI) patients as compared to the
general population [20, 21].
Although in the majority of cases of DVA men are per-
petrators and women are victims, in the last decade an
increasing amount of research showed that, at least
among psychiatric patients, men are often victims of
DVA as well [22–24]. In other words, despite the abso-
lute DVA prevalence in males is lower compared to
females, in psychiatric patients this gender difference is
greatly reduced. In patients the risk among men in-
creases steeply compared to the general population,
more so than in female psychiatric patients [13, 19, 21,
25]. This phenomenon is mostly overlooked.
In addition because of the social stigma associated
with (male) victims of DV and the few studies on male
victimization of DVA, under detection in general but in
males specifically, is likely as well.
Despite the evidence of a high risk for DVA in psychi-
atric patients and its serious consequences on patients
and their families, detection rates of DVA remain low.
Around 10–30% of cases are detected by psychiatric
service providers [26]. Clinicians often report barriers to
ask for experiences of concurrent DVA. These barriers
include the fear to confront and offend patients or the
fear to induce false memories [27], and perceived lack of
knowledge and expertise to address the abuse [28].
Moreover, after the detection of DVA, treatment plans
rarely take these experiences of DVA into account [25].
These figures are alarming and indicate that a great need
to invest in interventions to improve the identification
of DVA victimization and provision of mental health
services addressing the prevention of DVA (re-)
victimization among psychiatric patients. Although there
is little research on this subject, some have suggested
the use of an individual screenings tool to improve de-
tection of and outcomes for domestic violence in women
[29]. However, a Cochrane systematic review of screen-
ing in primary care found that this did not increase re-
ferrals to services specialized in DVA nor did it decrease
experienced DVA in victims [29]. These results suggest
that information dissemination on DVA to professionals
and patients and a screenings tool for DVA in isolation
does not create consistent, sustainable improvements in
identification and response to DVA.
As was shown in studies [13, 30], identification rate of
victims of DVA by health care professionals can increase
with a sustainable training of professionals and changes
in policy including the implementation of a referral and
care pathway within health care systems. Apart from a
positive effect on detection rate, these type of interven-
tions result in more referrals to specialist services for
DVA [13, 30].
The BRAVE study is informed by the Linking Abuse
and Recovery through Advocacy (LARA) pilot study in
mental health services and Identification and Referral to
Improve Safety (IRIS) cluster trial in primary care con-
ducted in the United Kingdom [13, 30], as both of these
studies showed promising results. Detection and referral
rates increased after a multi-faceted intervention was
provided to clinical teams which included training by
the DVA sector and a referral and care pathway which
included referral to the DVA sector; the level of func-
tioning and abuse experienced by psychiatric patients in
the LARA study was measured and also improved [31].
The BRAVE study is the first randomized controlled trial
which focuses on males and females who have a mental
illness.
The BRAVE study is an interventional study. The
intervention consists of: 1) a knowledge and skills train-
ing for mental health professionals about DVA, 2) know-
ledge and skills training of DVA practitioners about
mental illness, 3) the provision and implementation of a
direct referral pathway between community mental
health services and DVA services for victims of DVA
with mental illnesses. The effect of this intervention will
be tested in a cluster randomized controlled trial
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comparing the detection rate of domestic violence in
psychiatric patients of community mental health teams
in the intervention condition versus teams in the control
condition. Furthermore we aim to assess the feasibility,
sustainability and acceptance of the intervention for
clinicians, policy makers, managers and victims of DVA
in both the community mental health services and the
DVA services. We expect that the number of detected
cases of DVA will increase in the intervention group
compared to the control group.
Methods
Domestic violence and abuse services in context of the
public health system in the Netherlands
In the Netherlands, domestic violence and abuse (DVA)
services are part of the public health system. The public
health system is financed by government, and services
are free of charge for every citizen. The public health
services cover a wide range of problems, such as domes-
tic violence, youth work, and housing. Public health ser-
vices are the responsibility of the municipality. With
regards to DVA, starting from 2015, every municipality
in the Netherlands has installed a helpline service, for
both professionals and victims of DVA, named Veilig
Thuis (Safe Home).
A Veilig Thuis-service functions as a gatekeeper. They
assess cases of (suspected) DVA, provide advice in cases
of (suspected) DVA and coordinate referrals to third
party services on DVA. Veilig Thuis (VT) covers both
child abuse and intimate partner violence.
All municipal VT-services adhere to national DVA
guidelines (diagnostic and referral guidelines). These
guidelines are general in nature, which means that slight
differences in interpretation and execution may exist be-
tween municipalities.
Thus, the municipal care for victims of DVA offers the
following services [32].
Informal advice:
– Assessment: if a person calls the helpline, VT will
assess the situation during that phone conversation.
The helpline service is available for everyone with a
concern regarding DVA. This could be, for example,
a co-worker, victim of DVA or a clinician.
– Advice: after assessment VT will offer advice to
whomever using the helpline. This advice ranges
from passively monitoring the situation to notifying
the police because of a (potentially) dangerous
situation. VT can also give referral advice.
Formal advice:
– Assessment: the helpline can also be used for (health
care) professionals who want to ask for a formal
advice in a case of (suspected) DVA from VT. This
means that VT will be officially involved, they will
assess the situation in person and provide an official
report after their assessment which includes
directives for specialized services.
– Referral: after assessment, VT will refer the case for
the care they deem necessary to stop the violence.
This care can vary from empowerment courses
delivered by third party DVA services or social work
services to temporary eviction of the perpetrator. If a
case is deemed dangerous, VT can directly report
the case to the police and safeguard the victim
through admission in a safe house.
VT employs a variety of professionals namely, doctors
specialized in DVA behavioral experts, nurses. Most em-
ployees answering the helpline are social workers.
Legislation
All professionals working in health care are encouraged
to, and in the case of child abuse are obliged to, follow a
protocol on (suspicion of ) DVA by law. This protocol is
called ‘Meldcode’ [33]. Our aim is to improve and fur-
ther implement this protocol in daily practice as a part
of the referral pathway. The Meldcode consists of 5
steps a health care professional should follow when DVA
is suspected. The steps are: 1) screening for possible sig-
nals of DVA, 2) consultation of a colleague or a DVA
professional working at VT, 3) discuss suspicion of DVA
with the client/patient, 4) assessment of the severity of
the violence. In this step a consultation of a DVA profes-
sional at VT is possible, 5) patient referral to a service
specializing in DVA (if deemed appropriate) or a formal
assessment from VT. If at step 5 the health care profes-
sional decides to formally ask advice from VT, VT will
assess the situation and refer to/involve the care that
they think is needed to stop the violence.
Study setting
The study will be conducted in the municipalities of
Rotterdam and The Hague, the Netherlands. DVA
services provided in these municipalities are provided
by VT Rotterdam and VT The Hague (see previous
paragraph for details). Mental health care in these
municipalities is provided by two big community
mental health clinics (CMH) i.e. BAVO Europoort
(Rotterdam) and Parnassia The Hague. These clinics
provide both out-patient and in-patient mental health
care and cover the Rotterdam- Rijnmond and the
Hague area, which inhabits approximately 2.5 million
people. Service use is free of charge for all citizens
with health insurance, which is obligatory in the
Netherlands, after paying a limited contribution with
a maximum of 385 euros per year.
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Ethics
This design takes into account some important dilemmas
with regards to studying a population at risk for DVA. In
this study, screening for domestic violence is an integral
part of the intervention, because it is considered unethical
to screen for domestic violence while not offering any
kind of help to positively screened patients [34].
There is a high level of acceptance for screening
among women with severe mental illness [13, 28]. How-
ever, we need to protect professionals and patients from
violence as a consequence of disclosure of domestic vio-
lence by offering skills and information on how to assess
risk of and respond to violence. This theme will be a
substantial part of the training of professional and inter-
vention of the patient. Adverse events will be reported
to the researcher and scientific committee.
Professionals interested in taking part in the in-depth
interviews will be asked to sign an informed consent
prior to the interview. Professionals will be recruited by
the researcher.
Patients will be asked through their clinicians to par-
ticipate in an in-depth interview. If patients are inter-
ested they will receive an information letter about the
study and a researcher will approach the patient to ob-
tain informed consent.
With regards to our primary parameters, data will be
collected on team level, and cannot be traced back to indi-
vidual patients nor clinicians. Data of patients within
teams will be stored and analysed anonymously. With
regards to our secondary parameters, data on individual
professionals (the data of the short questionnaire on DVA
and the transcripts of the semi-structured interviews) will
be linked to subjects using an identification number. The
code list will be stored separately from the anonymous re-
search data, and secured by a password. All data will be
stored on local servers in designated folders. Only the re-
search group will have access to these folders. Data will be
handled by the research group only.
Due to the nature of this study, there will be no spe-
cific post-trial care. We do strive however, to implement
champions of DVA in each intervention team and sup-
port meetings where participants can ask questions
about complicated cases of DVA. While we strive to set
up support meetings, these meetings fall beyond the
scope of this study.
The Medical Ethical Committee of the Erasmus MC
Rotterdam approved the BRAVE study. All amendments
will also be approved by the Medical Ethical Committee
of the Erasmus MC Rotterdam before publication of any
published articles.
Dissemination
Trial results will be published in scientific journals.
Additionally main results will be communicated to the
participating mental health institutions. The trial is listed
on the ISRCTN registry with study ID ISRCTN14115257.
Study design
This study is a cluster randomized controlled trial. Clus-
ters in this trial are CMH teams working according to the
Flexible Assertive Community Treatment methodology
(FACT) [35].CMH teams provide outreaching care to pa-
tients with severe mental illness (SMI). A CMH team con-
sists of approximately 10 mental health professionals
including a psychiatrist, psychologist, social psychiatric
nurses and social workers. Their caseloads consists mostly
of patients with schizophrenia, psychosis, bipolar disorder
or chronic depression. The level of intensity of care can
vary over time and from patient to patient. Each CMH
team provides outreaching care for patients living in a cer-
tain district of The Hague or the Rotterdam – Rijnmond
area. The districts in this study are defined through postal
codes. CMH teams included in this study provide care for
approximately 200–250 patients.
Eligibility criteria for CMH teams
Subjects (teams) which meet any of the following criteria
will be excluded from participation in this study:
– Teams providing care to patients <18 years
– Teams with more than 20% of the employees
working over different teams
– Teams specialized in one specific mental illness (e.g.
autism)
– Teams without a functioning electronic patient file
system or with <12 months of historical data at the
start of the intervention.
Sample size
With regards to our primary research aim, we will test
the hypothesis that the intervention condition will result
in a significantly higher rate of detected cases of DVA
compared to the control condition over a 12 month fol-
low up period.
To calculate the sample size needed in this cluster
RCT, we started with a sample size calculation assuming
individual randomization and inflated this number by a
design effect to account for randomization by cluster
[36]. This inflation factor (IF) is dependent on average
cluster size, and the intra-class correlation (ICC). Using
this calculation we found that with a minimum of 12
intervention teams and 12 control teams, with the as-
sumption of a detection rate of 0.25% in control teams
(based on the LARA study [13]) and an ICC of 0.03
(based the IRIS study [30]) we will be able to detect a
three- to four-fold increase (Beta = 3.55) in the detection
rate with a power of 80% and a significance level of 0.05.
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This calculation assumes an average of 200 patients in
every team.
Regarding knowledge and attitudes on DVA, a sample
size of 24 teams allows us to detect a large sized increase
of knowledge between the intervention and control
teams.
In order to answer Aim 2 we will ask a purposeful
sample of persons from every profession involved in the
study for an in depth interview about the feasibility, sus-
tainability and acceptance of the intervention. A mini-
mum of ten interviewees will be selected from the DVA
services, and ten from CMH services. Furthermore all
trainers in this study will be interviewed on their experi-
ences. Additionally, we will interview a total of 30 pa-
tients or more until saturation of the themes is achieved.
Recruitment
The CMH teams eligible for inclusion will be appointed
by the management of the participating facilities to par-
ticipate in the trail.
Recruitment regarding the in-depth interviews on
feasibility, sustainability and acceptability will be done by
the research team. All professionals participating in the
study will be asked if they want to participate in an
interview. Patients will be approached through their pri-
mary clinician at the CMH team. If a patient is inter-
ested they can contact the research team for further
information and possible participation. Additionally we
will recruit patients through patient support organiza-
tions, support groups for victims of DVA, and advertise-
ments placed at the locations of the CMH services.
Interested patients will be provided with an information
letter on the study. After signing informed consent the
patient will approached for an interview. We will inter-
view patients until saturation of the themes is achieved.
Patients will receive a fee of 20 euros after the interview.
Randomization and blinding
We will randomly allocate the 24 CMH teams in a 1:1 al-
location ratio to receive either no intervention or the
BRAVE intervention. Randomization will be conducted
using a web-based computer-generated randomization
schedule ten-ALEA (randomization software programme,
version 2.2), using block sizes of 2. Social-economic status
of the service area of the CMH team dichotomized into
high and low social-economic status, will be used as strati-
fication factor. Allocation will be facilitated by an inde-
pendent researcher. Due to the nature of this intervention,
it is not possible to blind the CMH professionals of the
teams for allocation status. An independent researcher,
blinded for allocation, will be responsible for extracting
the primary data fields regarding the primary outcome
measure (e.g. the number of screened DVA cases per
team) from the electronic patient files.
Intervention
The intervention consists of 1) knowledge and skills
training for mental health professionals of the CMH
teams about DVA, 2) knowledge and skills training of
DVA practitioners about mental illness, 3) the provision
and implementation of a direct care pathway between
CMH services and DVA services for victims of DVA
with mental illness.
1) Knowledge and skills training for mental health
professionals about DVA:
The training for the teams has been developed by the
research team and is aimed at improving knowledge and
skills regarding detection and management of DVA. At
the start of the trial, all CMH teams in the intervention
group will receive a training of approximately 8 hour in
total, divided over 2 days. The topics covered in the
training used in the LARA-intervention were included
here [13] and consist of four main themes namely;
– Improving knowledge about DVA; (the definition
and different forms of DVA; prevalence and
incidence of DVA in the Netherlands; and
symptoms and signals of DVA, including cultural
differences in expression).
– Identifying and documentation of DVA when taking
the patient’s history: this theme will cover different
techniques a clinician can use to discuss and assess
DVA with a patient and includes advice on how to
document DVA.
– Safety: this theme entails safety assessment and
management for patients and clinicians and will also
include laws and legislation on DVA in the
Netherlands.
– Treatment/follow up: this theme will discuss referral
pathways and ways to empower/support patients
who are victims of DVA.
The training is modified according to the
characteristics of the specific municipality. This
means that the teams will receive training with a
referral pathway adapted to the Rotterdam and The
Hague municipality, respectively.
Implementation
All members of a CMH team randomized in the inter-
vention condition will be invited to attend the training.
Attendance will be monitored. During, and after initial
training, teams are actively encouraged to implement
the techniques learned in their daily practice.
After the training, clinicians will receive an extended
manual incorporating good practice guidelines and in-
formation on local/national DVA services. To improve
implementation of the knowledge gained in the training,
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each team in the intervention condition will be recom-
mended to assign a advocate on DVA. Advocates in the
intervention teams will collect all problems and ques-
tions regarding DVA in their team. We will maintain
close contact with the DVA advocates throughout the
study through e-mail. Advocates can address problems
in the collaboration with DVA practitioners and/or refer-
ral to DVA services to the DVA expert team in the insti-
tution. This expert team is not part of this study and is
already in place at the two participating institutions be-
fore the beginning of this study. We will also hand out
posters with conversational techniques on DVA and
cards team members can use as an aid when talking to
their patients about DVA.
The teams in the control condition will not receive
any additional training in DVA. Clinicians in the control
condition however, can refer patients to DVA service-
s(according to standard practice), when they detect a pa-
tient suffering from DVA.
2) Knowledge and skills training of DVA practitioners
about mental illness:
The professionals working at VT will be offered train-
ing on mental illness and procedures within mental
health care. The training has been developed by the re-
search team and can be adjusted according to the base-
line level of knowledge of the professionals working at
VT. Regardless of adjustment, the training consists of a
the following key elements:
– Knowledge on mental illness (including
conversational techniques and pitfalls and
possibilities in dealing with psychiatric illness)
– Structure of mental health care services and patient-
doctor confidentiality
– Referral to and communication with clinicians
working in mental health care
3) The provision and implementation of a direct care
pathway between CMH services and DVA services for
victims of DVA with mental illness
Our study will focus on providing professionals work-
ing in mental health care with the necessary skills refer
victims of DVA to services specializing in DVA and to
implement the Meldcode protocol as part of the referral
pathway in daily practice. The Meldcode is explained in
more detail in the section legislation. Professionals will
be provided with a visual outprint of the Meldcode, con-
tact information on local DVA services and information
on resources on DVA in their own organization in the
manual of the training. Every professional has access to
a work related smartphone and professionals will be
encouraged to install the Meldcode app.
Outcome measures, aims and data collection
Primary outcome
The primary outcome measure is the rate of detected of
DVA cases per CMH-team, taking into account the
number of patients in each team. Outcomes will be ob-
tained through a systematic search in electronic patient
files at the participating mental health institutions. We
will search the electronic patient files using a set of key-
words, their synonyms, (miss-)spellings and words
closely associated with DVA. Our main keyword will be
domestic violence. This keyword will first be piloted and
validated. A specialized software program will be used to
analyze the information in the electronic patient files of
the detected cases to determine words closely associated
with domestic violence. To validate the detected cases,
we will assess each detected case of DVA individually
using information from the electronic patient file. Non-
cases will be verified randomly. Reliability of the data ex-
traction will be evaluated by repeating the data extrac-
tion on a subset of teams by a second independent
researcher and compare the outcomes. To ensure com-
parability in timing, we will pair control and interven-
tion teams and obtain outcome data simultaneously. We
expect an underreporting of detected cases and over-
reporting of referred cases by the clinicians in the pa-
tient records [30]. Since these biases will affect both
intervention and control condition equally, study results
will remain valid.
Secondary aims and outcomes
The BRAVE intervention has the following secondary
aims and outcomes:
Aim 1 - to assess gains and sustainability in knowledge
on DVA among mental health professionals.
Aim 2 - to assess the feasibility, sustainability and
acceptance of the intervention among CMH teams and,
Aim 3 - to assess the (possible) referral pathway to
DVA services and the implementation of the Meldcode.
We will assess Aim 1 using a structured questionnaire
– The BRAVE Survey - developed specifically by the
study team, to assess CMH teams knowledge and atti-
tudes regarding DVA.
Aim 1 - the BRAVE survey
The BRAVE survey was informed by the PREMIS [37]
and PROTECT questionnaires [38].
All members of the included teams will receive this
survey. The survey has a total of 53 questions divided
into 5 sections: (1) Respondent profile, (2) Previous
Courses on DVA (3) Skills in management of DVA, (4)
Knowledge on DVA and (5) Opinions on DVA. Section
1; “Respondent profile” consists of 7 questions, of which
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3 are multiple choice and 4 questions an individual can
fill in. Participants are asked about their professional
background (work experience, current profession, educa-
tional level) and general information (date, age, gender);
section 2; “Previous courses attended on DVA” consists
of a multiple choice question about previous courses on
DVA. If participants check yes they are asked 4 ques-
tions about duration of this course and when this
course was completed. Section 3; “Skills in manage-
ment of DVA” consists out of 7 multiple choice state-
ments. Participants can check the box on the Likert
scales, ranging from 1 (not skilled) to 5 (very skilled),
the extent to which they feel skilled to handle/judge a
particular described situation regarding DVA. Section
4; “Knowledge on DVA” consists of a total of 14 mul-
tiple choice statements. For the first three questions,
participants need to check the box on Likert scales,
ranging from 1 (nothing) to 5 (a lot). These questions
are followed by 10 multiple choice questions with
statements about DVA where participants can choose
between true (1) and not true (2). The last question
in this section asks the participants to combine the
correct described statement with the right stage of
the process of discontinuing a relationship with a per-
petrator. Section 5; “Opinions on DVA” consists of 16
statements on DVA where participants can choose
whether they agree on a Likert scale ranging from 1
(do not agree) to 5 (agree).
To be able to compare the scores of the survey, sec-
tions 3 (Skills), 4 (Knowledge) and 5 (Opinions) will be
calculated separately per participant and will then be ag-
gregated at a team level. Qualitative answers will be
given a score and, post-hoc assigned to answering cat-
egories. Statistical comparisons will be made between
intervention and control teams.
This questionnaire will be assessed at baseline, after
6 months of the intervention and after 12 months of the
intervention.
We will assess Aim 2 by conducting semi struc-
tured in-depth interviews with members of CMH
teams, policy makers, patients and DVA practitioners
about the feasibility, sustainability and acceptance of
the intervention.
Aim 2 Semi-structured in depth interviews
We will obtain outcomes regarding opinions on
feasibility, sustainability and acceptance of the inter-
vention using a semi-structured in depth interview
with a purposive sample of professionals in the inter-
vention - and control group, team-leaders, managers,
patients in the intervention group, patients in the
control group, patients who have experienced DVA
and patients who didn’t experience DVA. The inter-
view for clinicians will mostly focus on their opinions
and personal definition of the following themes:
– DVA
– actions (not) taken
– referral pathways between CMH services and DVA
services
– impact of the intervention on care provision and
care professionals (including personal safety)
– impact of the intervention on client relationship
– impact of the intervention on client wellbeing
(including personal safety)
– level of implementation of the intervention in daily
practice
– feasibility of implementation of the intervention
– sustainability of the intervention
In the policy makers of the included mental health in-
stitution and team managers the in depth interview will




– referral pathways between CMH and DVA services
– level of collaboration between CMH and DVA
services
– impact of the intervention on care provision and
operational capability
– cost-effectiveness of the intervention
The in depth interview with psychiatric patients will
focus on their opinions and personal definition of the
following themes:
– DVA
– disclosure of DVA
– available help for DVA
We will gather data until saturation of the theoretical
framework (what is the feasibility, sustainability and
acceptance of the intervention as well as how was the
intervention implemented). Interviews will be recorded
and transcribed as preparation for analysis. We will
analyze the data with a mix of content and framework
analysis. After the frameworks are identified, the data
will be structured, labelled and coded.
We will assess aim 3 using the detected cases from the
primary outcome. We will then search electronic patient
files of the detected cases to identify cases of DVA re-
ferred to professional DVA services per included CMH
team.
Aim 3 Evaluation of the referral pathway to profes-
sional services on DVA of detected cases
Detected cases are extracted from the electronic pa-
tient’s files using the method described in the section
‘Primary outcome’ of this article. Of all detected cases of
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DVA the following information, will be extracted from
the electronic patient file, when available: 1) the time
from disclosure of DVA to referral, 2) details on any
consultation with VT and/or colleagues, including the
possible reason for consultation and advice given; 3) if
the patient was involved in the decision to engage with
VT and/or colleagues and their opinion about the given
advice; 4) how the severity of the DVA case was assessed
and which sources were used for the assessments; 5)
details on the referral process, Including the reasons for
the formal request for advice/ informal advice from VT,
reasons for the ultimate decision to refer/not to refer,
details of the referral site, the care provided at the
referred institution, and outcomes for the patient with
regards to the (ending of ) violence. In doing so, we aim
to assess the qualitative characteristics of the referral
pathway in the intervention and control teams.
Statistical methods
The number of DVA cases detected per team
We will use Generalized Estimating Equations analysis
to compare detection rate in the intervention and con-
trol teams. Independent variables will be number of de-
tections each CMH team over 12 month follow-up
period. The number of patients in each CMH team will
be included as denominator, and CMH team will be in-
cluded as a random effect to take the clustered nature of
the data into account. Subsequent analysis will be ad-
justed for the number of detected cases at baseline. Sen-
sitivity analyses will be conducted to evaluate the impact
of team characteristics (such as case load size, propor-
tion of clinicians trained on DVA, and proportion of fe-
male patients) on the intervention outcomes. Due to the
nature of our study, we will not have any missing data.
Survey on knowledge and attitudes on DVA
Subscale scores from BRAVE survey will be calculated.
For each participant change scores will be calculated be-
tween baseline and follow-up score. Generalized Esti-
mating Equations analysis will be used to compare mean
change score in the intervention and control teams. The
CMH team will be included as a random effect to ac-
count for the clustering of the data. Questionnaires with
more than 5% of the questions missing will be removed
from the sample. Questionnaires with less than 5% miss-
ing will be imputed using multiple imputation.
Fidelity scale
Fidelity of the BRAVE intervention will be assessed by
an independent researcher during the intervention at the
time points of 6 and 12 months. A fidelity scale will
assess whether 5 key components of the intervention are
in place 1) training for mental health professionals on
DVA, 2) training for DVA practitioners on mental
health, 3) identification of the components of DVA in
routine mental health care, 4) Integrated DVA referral
and care pathway 5) collaboration between DVA special-
ists and mental health professionals. The fidelity scale
was developed in collaboration with the LARA research
group.
Data monitoring
This is a low risk study, a full data monitoring commit-
tee is not deemed necessary. A monitor and data archiv-
ing plan is in place.
Assessment schedule
All teams eligible for participation will be included be-
fore the start of the intervention. After inclusion, teams
will be assigned randomly to the control condition and
intervention condition. All teams will receive a baseline
assessment, an assessment at 6 months and an assess-
ment at 12 months using the BRAVE survey. The num-
ber of detected cases of DVA will be studied over a 1
year period. The in-depth interviews will be conducted
in the last period of the intervention period and after
the intervention period (Table 1).
Discussion
DVA is a problem worldwide and particularly vulnerable
groups, such as psychiatric patients with severe mental
illness, become victims of DVA while at the same time
DVA often remains undetected in this group by mental
health professionals. In this protocol, we will measure
the efficacy of an intervention to improve knowledge
and skill training for professionals about DVA and men-
tal illness, as well as to implement a referral pathway
between CMH and DVA services for DVA victims with
mental illness. According to these premises, we under-
line the importance of this intervention for psychiatric
patients suffering from DVA.
This study is the first cluster randomized controlled
trial targeting both male and female psychiatric patients
who potentially experience DVA, using an intervention
that involves a training of mental health and DVA ser-
vices, and the focus on the implementation of a referral
protocol. Among victims of DVA, loss to follow up is
considered a risk. MacMillan et al. [34] reported 42%
loss over an 18 months follow up period. This high per-
centage loss is partly due to the nature of the problem
studied. Victims of DVA show a high level of mobility
and might be at high risk for subsequent violence after
disclosure of the DV. By assessing our primary outcomes
at team level, we minimize biases caused by individual
drop out.
Furthermore, by randomizing teams we avoid contam-
ination of skills and techniques of professionals in the
intervention condition to the professionals in the control
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condition. However, since a cluster RCT is less precise
than an individual trail, the chance of failing to detect a
true intervention effect might increase (type II error).
Also, the number of clusters in this trail is relatively small
(i.e. 24 clusters), therefore randomization might partly fail,
which would cause the patients in the control and inter-
vention condition to differ from each other [39].
We do not foresee many risks in the attainment of this
study. However, possible risks could occur if the mental
health institutions discontinue facilitation of the CMH
teams or reorganize the team structure, for instance by
merging existing teams during the study period. This
will affect the number, size and composition of clusters.
This might lead to contamination and decrease of
power. Also, municipal reorganization of the DVA
services might affect the attainment of this study.
With better detection rates of DVA, the focus of
research on this topic could shift towards improvement
of treatment, prevention and interventions on DVA on
an individual level.
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